| Schedule of Restatement on Financial Statements |
The accompanying notes to the unaudited consolidated interim financial statements have been restated as applicable.
|
|
|
|
As Previously Reported
|
|
|
|
Adjustment
|
|
|
|
As Restated
|
|
|
Balance Sheet as of September 30, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant liability
|
|
$
|
—
|
|
|
$
|
|
215,705
|
|
|
$
|
|
215,705
|
|
|
Total current and long term liabilities
|
|
$
|
|
2,456,293
|
|
|
$
|
|
215,705
|
|
|
$
|
|
2,671,998
|
|
|
Additional paid-in capital
|
|
$
|
|
51,467,127
|
|
|
$
|
|
755,625
|
|
|
$
|
|
52,222,752
|
|
|
Accumulated deficit
|
|
$
|
|
(39,090,204
|
)
|
|
$
|
|
(971,330
|
)
|
|
$
|
|
(40,061,534
|
)
|
|
Total stockholders equity
|
|
$
|
|
12,326,372
|
|
|
$
|
|
(215,705
|
)
|
|
$
|
|
12,110,667
|
|
|
Statement of Operations, Three Months Ended September 30, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratchet share expense
|
|
$
|
|
—
|
|
|
$
|
|
1,099,360
|
|
|
$
|
|
1,099,360
|
|
|
Loss from operations
|
|
$
|
|
(3,996,226
|
)
|
|
$
|
|
(1,099,360
|
)
|
|
$
|
|
(5,095,586
|
)
|
|
Change in fair value of warrant liability
|
|
$
|
—
|
|
|
$
|
|
128,030
|
|
|
$
|
|
128,030
|
|
|
Other income (expense) net
|
|
$
|
|
63,743
|
|
|
$
|
|
128,030
|
|
|
$
|
|
191,773
|
|
|
Net Loss
|
|
$
|
|
(3,932,483
|
)
|
|
$
|
|
(971,330
|
)
|
|
$
|
|
(4,903,813
|
)
|
|
Deemed dividend on ratchet shares
|
|
$
|
|
(1,099,360
|
)
|
|
$
|
|
1,099,360
|
|
|
$
|
|
—
|
|
|
Net loss attributable to MAIA Biotechnology, Inc.
shareholders
|
|
$
|
|
(5,031,843
|
)
|
|
$
|
|
128,030
|
|
|
$
|
|
(4,903,813
|
)
|
|
Net loss per share; basic and diluted
|
|
$
|
|
(0.49
|
)
|
|
$
|
|
0.01
|
|
|
$
|
|
(0.48
|
)
|
|
Statement of Operations, Nine Months Ended September 30, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ratchet share expense
|
|
$
|
|
—
|
|
|
$
|
|
1,099,360
|
|
|
$
|
|
1,099,360
|
|
|
Loss from operations
|
|
$
|
|
(10,881,828
|
)
|
|
$
|
|
(1,099,360
|
)
|
|
$
|
|
(11,981,188
|
)
|
|
Change in fair value of warrant liability
|
|
$
|
—
|
|
|
$
|
|
128,030
|
|
|
$
|
|
128,030
|
|
|
Other income (expense) net
|
|
$
|
|
229,617
|
|
|
$
|
|
128,030
|
|
|
$
|
|
357,647
|
|
|
Net loss
|
|
$
|
|
(10,652,211
|
)
|
|
$
|
|
(971,330
|
)
|
|
$
|
|
(11,623,541
|
)
|
|
Deemed dividend on ratchet shares
|
|
$
|
|
(1,099,360
|
)
|
|
$
|
|
1,099,360
|
|
|
$
|
|
—
|
|
|
Net loss attributable to MAIA Biotechnology,
Inc. shareholders
|
|
$
|
|
(12,202,149
|
)
|
|
$
|
|
128,030
|
|
|
$
|
|
(12,074,119
|
)
|
|
Net Loss per share; basic and diluted
|
|
$
|
|
(1.40
|
)
|
|
$
|
|
0.01
|
|
|
$
|
|
(1.39
|
)
|
|
Statement of Changes in Condensed Consolidated Statement of Comprehensive Loss Three Months Ended September 30, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to MAIA Biotechnology,
Inc. shareholders
|
|
$
|
|
(5,031,843
|
)
|
|
$
|
|
128,030
|
|
|
$
|
|
(4,903,813
|
)
|
|
Comprehensive loss to MAIA Biotechnology, Inc.
shareholder
|
|
$
|
|
(5,079,344
|
)
|
|
$
|
|
128,030
|
|
|
$
|
|
(4,951,314
|
)
|
|
Statement of Changes in Condensed Consolidated Statement of Comprehensive Loss Nine Months Ended September 30, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable to MAIA Biotechnology, Inc. shareholders
|
|
$
|
|
(12,202,149
|
)
|
|
$
|
|
128,030
|
|
|
$
|
|
(12,074,119
|
)
|
|
Comprehensive loss to MAIA Biotechnology, Inc.
shareholder
|
|
$
|
|
(12,253,795
|
)
|
|
$
|
|
128,030
|
|
|
$
|
|
(12,125,765
|
)
|
|
Statement of Changes in Stockholders’ Equity (Deficit), Three Months Ended September 30, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deemed dividend on ratchet shares
|
|
$
|
|
(1,099,360
|
)
|
|
$
|
|
1,099,360
|
|
|
$
|
|
—
|
|
|
Net loss
|
|
$
|
|
(3,932,483
|
)
|
|
$
|
|
(971,330
|
)
|
|
$
|
|
(4,903,813
|
)
|
|
Additional paid-in capital at September 30, 2022
|
|
$
|
|
51,467,127
|
|
|
$
|
|
755,625
|
|
|
$
|
|
52,222,752
|
|
|
Accumulated deficit at September 30, 2022
|
|
$
|
|
(39,090,204
|
)
|
|
$
|
|
(971,330
|
)
|
|
$
|
|
(40,061,534
|
)
|
|
Total equity at September 30, 2022
|
|
$
|
|
12,326,372
|
|
|
$
|
|
(215,705
|
)
|
|
$
|
|
12,110,667
|
|
|
Statement of Cash Flows, Nine Months Ended September 30, 2022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss, including noncontrolling interests
|
|
$
|
|
(10,652,211
|
)
|
|
$
|
|
(971,330
|
)
|
|
$
|
|
(11,623,541
|
)
|
|
Change in fair value of warrant liability
|
|
$
|
|
—
|
|
|
$
|
|
(128,030
|
)
|
|
$
|
|
(128,030
|
)
|
|
Issuance of ratchet shares
|
|
$
|
—
|
|
|
$
|
|
1,099,360
|
|
|
$
|
|
1,099,360
|
|
|
Net cash used in operating activities
|
|
$
|
|
(9,146,390
|
)
|
|
$
|
|
0
|
|
|
$
|
|
(9,146,390
|
)
|
|